Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
NCT03212521
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
230
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C Virus (HCV)
Interventions
DRUG:
Glecaprevir/Pibrentasvir
Sponsor
AbbVie